Sonoma Pharmaceuticals, Inc. — Form 10-K Summary
Reporting period: Fiscal year ended March 31, 2021, compared with the year ended March 31, 2020. Although the request metadata says “2020 Q4,” this filing reports annual results, not standalone quarterly results. Amounts below are U.S. dollars.
Business context
Sonoma develops and manufactures stabilized hypochlorous acid (HOCl) products for wound care, dermatology, eye, oral and nasal care, animal health, and disinfectants. It sells directly and through partners in 54 countries. During fiscal 2021, it completed a restructuring, moved manufacturing from California to Mexico, and expanded its distribution-partner strategy.
Financial performance and liquidity
| Metric | FY2021 | FY2020 |
|---|---|---|
| Total revenue | $18.629 million | $17.928 million |
| Gross profit / gross margin | $6.559 million / 35% | $8.122 million / 45% |
| Operating expenses | $10.008 million | $15.512 million |
| Loss from continuing operations | $4.615 million | $3.573 million |
| Net loss | $3.950 million | $3.308 million |
| Net loss per share, basic and diluted | $1.97 | $2.24 |
| Net cash used in operations | $3.378 million | $4.591 million |
Cash and cash equivalents were $4.220 million at March 31, 2021, versus $3.691 million a year earlier. Working capital was $8.905 million, versus $7.554 million. Total liabilities were $9.624 million and stockholders’ equity was $5.363 million. Debt included a $1.310 million PPP loan, reported as long-term debt, and $596,000 of current long-term debt. The company said it expected approximately $730,000 of PPP loan forgiveness; forgiveness was not reported as completed in the provided filing text.
FY2021 revenue was $5.419 million in the United States, $5.976 million in Latin America, and $7.234 million in Europe and the rest of the world. Approximately 71% of total revenue was generated outside the United States, versus 55% in FY2020.
Changes versus the prior year
- Revenue rose 4%, but gross profit fell 19% and gross margin declined 10 percentage points, to 35%. Management attributed the margin decline mainly to product mix, including lower-margin Invekra sales and a greater distributor-sales mix.
- U.S. revenue fell 32%, primarily due to reduced dermatology sales amid COVID-19 disruptions and restructuring. Latin America revenue increased with large Invekra orders, while Europe and rest-of-world revenue also grew.
- Research and development expense declined 59% to $555,000, following closure and relocation of the Seattle R&D facility. Selling, general and administrative expense fell 33% to $9.453 million, reflecting sales-force reductions and facility consolidation.
- Operating loss improved to $3.449 million from $7.390 million, but the prior year included $3.572 million of asset-sale gains. The continuing-operations loss widened, and net loss increased.
- Other expense was $594,000, compared with $240,000 of other income in FY2020, largely reflecting foreign-exchange losses of approximately $690,000 versus gains of $306,000.
- The Micromed testing business was sold in June 2020 and reported as discontinued operations. The sale generated a $770,000 pre-tax disposal gain; discontinued operations contributed $665,000 after tax in FY2021.
Outlook, risks and unusual items
- Going concern: The auditor included an explanatory paragraph stating that substantial doubt exists about the company’s ability to continue as a going concern. Management expects losses to continue and says additional capital may be needed; it cannot assure financing will be available on acceptable terms.
- Commercial outlook: The five-year EMC Pharma agreement gives EMC exclusive U.S. rights to sell prescription dermatology and eye-care products, subject to minimum purchases and other conditions. Management expects lower reported dermatology revenue at transfer prices, offset by reduced sales-force overhead. No quantified revenue or earnings guidance is provided.
- Invekra transition: The reduced-price supply agreement ended October 27, 2020. Large orders supported FY2021 Latin American revenue, but the company expects Invekra-related and overall Latin American revenue to decline as Invekra moves to its own manufacturing; future manufacturing support may be at market prices.
- COVID-19: The pandemic supported some international disinfectant sales but disrupted prescription dermatology and other product sales, as well as supply chains. The filing says the full future impact remained uncertain.
- Tax and intercompany exposure: The Mexico subsidiary’s intercompany debt was approximately $11.0 million principal, $6.0 million technical-assistance payments and $17.5 million accrued interest. Mexican tax rules restrict interest deductions; the filing cites approximately $3.5 million of potential Mexican withholding tax if relevant balances were repaid and approximately $900,000 of Mexico tax paid for FY2021. The company also corrected an immaterial prior-period withholding-tax accrual error without restating previously issued statements.
- Controls and audit: Management concluded disclosure controls and internal control over financial reporting were ineffective at March 31, 2021, citing material weaknesses that included spreadsheet controls, segregation of preparation and review, revenue analysis, and income-tax accruals. Remediation was underway but not yet considered complete. The auditor’s opinion on the financial statements was unqualified; the auditor did not audit internal control effectiveness.
- Concentration and other risks: Two customers represented 32% and 15% of FY2021 net revenue. Other key exposures include reliance on distributors, foreign exchange, regulatory clearances, product liability, manufacturing quality, intellectual property, and the need for further capital. The filing reports no material off-balance-sheet arrangements and says ordinary-course legal matters were not considered significant by management.
Important facts for investors to verify
- Whether Sonoma can obtain additional financing and sustain operations given recurring losses, operating cash outflows, and the auditor’s going-concern warning.
- Whether the EMC partnership generates profitable sales and meets its minimum-purchase and exclusivity requirements.
- The pace and financial impact of Invekra’s transition to in-house manufacturing, including replacement revenue and resulting margins.
- Whether PPP loan forgiveness was obtained and how the remaining loan balance and Mexico-related tax and withholding exposures evolve.
- Whether management remediates and tests the disclosed material weaknesses in financial reporting controls.
- How customer concentration, overseas revenue exposure, COVID-related recovery, and the decline in gross margin affect future results.